Security key
23284F105
CytomX Therapeutics, Inc. - Common Stock, $0.00001 par value per share ("Common Stock") (CTMX)
CUSIP: 23284F105
Q3 2022 13F Holders as of 30 Sep 2022
- Security type / class
- Equity / Common Stock, $0.00001 par value per share ("Common Stock")
- Total 13F shares
- 36,281,610
- Total 13F value
- $52,604,898
- Share change
- -9,536,047
- SEC-reported price per share
- $1.45
- Number of holders
- 76
- Value change
- -$18,986,577
- Number of buys
- 31
- Number of sells
- 42
- Shares outstanding
- 217,079,600
Holder snapshot
6 signals
Security identity
Names, identifiers, and filing context for this profile.
1 source field
Report period
Q3 2022
Institutions
76
Top holders
10
CTMX full security history
Ownership snapshot
Full 13F holder table
Newer quarter: Q4 2022
Previous quarter: Q2 2022
CytomX Therapeutics, Inc. SEC filings
CytomX Therapeutics, Inc. company facts
Broader feeds
Reporting periods
Holder history for CUSIP 23284F105
Recent filing periods:
Ownership snapshot
Top reported holders of CTMX - CytomX Therapeutics, Inc. - Common Stock, $0.00001 par value per share ("Common Stock") (13F + 13D/G + 3/4/5)
Grouped by holder across the latest SEC ownership disclosures. Start with comparable ownership when available, then verify the linked 13F, 13D/G, or 3/4/5 evidence.
Comparable stake leader
BVF INC/IL
Disclosed value leader
BVF INC/IL
Comparable rows
15/15
Latest evidence
30 Jun 2022
13F
Lead comparable stake: 2.7%
Showing 1-6 of 15 holder rows.
Quick read
BVF INC/IL leads the comparable SEC ownership view at 2.7%.
15 of 15 rows have a safely comparable ownership percentage. Use this as a filing-backed starting point, then open the detailed table for source links, reporting role, position value, share count, and filing date.
Open SEC evidence
Opens BVF INC/IL's linked filing trail.
Comparable ownership
Top 5
BVF INC/IL
2.7%
VANGUARD GROUP INC
2.3%
RTW INVESTMENTS, LP
1.3%
Point72 Asset Management, L.P.
1.3%
Rubric Capital Management LP
1.1%
Ownership % is shown only when SEC disclosures are safely comparable across share classes.
Detailed SEC evidence table Showing 1-6 of 15 holder rows
| Holder | Evidence | Ownership % | Position | 12M Net Δ | As of |
|---|---|---|---|---|---|
| BVF INC/IL |
13F
Company
|
2.7%
|
$10,621,000
5,803,700 shares
|
— | 30 Jun 2022 |
| VANGUARD GROUP INC |
13F
Company
|
2.3%
|
$9,294,000
5,078,387 shares
|
— | 30 Jun 2022 |
| RTW INVESTMENTS, LP |
13F
Company
|
1.3%
|
$5,215,000
2,849,707 shares
|
— | 30 Jun 2022 |
| Point72 Asset Management, L.P. |
13F
Company
|
1.3%
|
$5,033,000
2,750,000 shares
|
— | 30 Jun 2022 |
| Rubric Capital Management LP |
13F
Company
|
1.1%
|
$4,404,000
2,406,449 shares
|
— | 30 Jun 2022 |
| ORBIMED ADVISORS LLC |
13F
Company
|
0.98%
|
$3,889,000
2,124,975 shares
|
— | 30 Jun 2022 |
How to read this table
Rows are grouped by holder and ranked first by SEC-reported ownership % when it is safely comparable, then by disclosed holdings value. — indicates unavailable or non-comparable values; "mixed-class rows" means the latest filing spans non-comparable classes.
13F holder rows
Institutional holders as of Q3 2022
Investor-level positions for this CUSIP, loaded as an interactive table.
Institutions
76
Shares
36,281,610
Rows available
76
| Investor | Option | Weight % | Change % | SEC-reported value | * Price | Shares | Share Change | Activity | Report Period |
|---|
* SEC-reported price is the security price as of the portfolio date and can indicate the last known price at which the security was still held. The marker flags a reported price that did not pass the local price check.
Compare Q3 2022 vs Q2 2022 Across Filers
Q2 2022 holders
86
Q3 2022 holders
76
Holder diff
-10
| Investor | Q2 2022 Shares | Q3 2022 Shares | Share Diff | Share Chg % | Q2 2022 value | Q3 2022 value | Value change | Value Chg % |
|---|
Trend: ostatnie 8 kwartałów (+ wybrane okresy porównania).
Quarterly Holders Trend
Quarterly Value Trend
Quarterly Shares Trend